Back to results
US 2017/0247706 A1Published application
Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paul Sabatier Toulouse III
InventorsStéphane MANENTI, Sarah BERTOLI
Life of this patent
Estimating the term…
Abstract
The present invention concerns a CDC25A phosphatase inhibitor for use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering or having suffered from cancer.
Claims11
A method of treating drug resistant acute myeloid leukemia (AML) and/or for preventing tumor relapses in a patient suffering or having suffered from acute myeloid leukemia, comprising
- administering to the patient an effective amount of a CDC25A phosphatase inhibitor.
A pharmaceutical composition comprising:
- i. a CDC25A phosphatase inhibitor;
- ii. a pharmaceutically acceptable carrier;
- and
- iii. optionally a chemotherapeutic drug.
1 more element
8-9. (canceled)
Dependencies are inferred from the claim text.